Document Detail


Beneficial effects of statins after percutaneous coronary intervention.
MedLine Citation:
PMID:  19369875     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Evidence about the efficacy of statin treatment among patients after percutaneous coronary intervention (PCI) is very limited. The rapid advancement in PCI technology and near universal use of adjunctive cardioprotective medications make it necessary to formally assess the effect of statin therapy on cardiac events after PCI.
DESIGN: This was a multicenter prospective cohort study.
METHODS: Patients who received stent implantation and survived to hospital discharge from the National Heart, Lung, and Blood Institute Dynamic Registry from 2004 to 2006 formed the study cohort. Patients with cardiogenic shock, in-hospital adverse events [including myocardial infarction and coronary artery bypass graft surgery (CABG)], liver disease, renal disease, alcoholism, or drug abuse were excluded. The occurrences of death, CABG, and repeat PCI, and repeat revascularization were collected over 1-year follow-up.
RESULTS: Of the 3227 patients evaluated, 2737 (85%) were prescribed a statin at discharge. By 1-year follow-up, incident events were 98 deaths, 44 CABG, 290 repeat PCI procedures, and 328 repeat revascularizations. After propensity score adjustment, postdischarge statin therapy was associated with lower risks of death [hazard ratio (HR): 0.58, 95% confidence interval (CI): 0.36-0.93, P = 0.02], CABG (HR: 0.49, 95% CI: 0.24-1.00, P = 0.05), and repeat revascularization (HR: 0.74, 95% CI: 0.56-1.00, P = 0.05).
CONCLUSION: These results support the routine use of statin therapy after PCI.
Authors:
Zhi-Jiang Zhang; Oscar C Marroquin; Joel L Weissfeld; Roslyn A Stone; Suresh R Mulukutla; David O Williams; Faith Selzer; Kevin E Kip
Related Documents :
15869905 - Haematoma after coronary angiography and percutaneous coronary intervention via the fem...
24327645 - Late bidirectional glenn anastomosis in a 54-year-old patient with unoperated functiona...
24406815 - Hydrogel based injectable scaffolds for cardiac tissue regeneration.
24080085 - Humoral control of cardiac remodelling in fish: role of angiotensin ii.
16564665 - Multi-slice computer tomography of left ventricular function with automated analysis so...
25226755 - Rare case of bland white-garland syndrome with myocardial infarction in paediatrics.
Publication Detail:
Type:  Journal Article; Multicenter Study; Research Support, N.I.H., Extramural    
Journal Detail:
Title:  European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology     Volume:  16     ISSN:  1741-8275     ISO Abbreviation:  Eur J Cardiovasc Prev Rehabil     Publication Date:  2009 Aug 
Date Detail:
Created Date:  2009-07-30     Completed Date:  2009-10-29     Revised Date:  2013-06-02    
Medline Journal Info:
Nlm Unique ID:  101192000     Medline TA:  Eur J Cardiovasc Prev Rehabil     Country:  England    
Other Details:
Languages:  eng     Pagination:  445-50     Citation Subset:  IM    
Affiliation:
Department of Epidemiology, School of Public Health, Shanghai Jiao Tong University, Shanghai, China. zhz232@gmail.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Chi-Square Distribution
Combined Modality Therapy
Coronary Disease / therapy*
Female
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
Linear Models
Male
Middle Aged
North America
Proportional Hazards Models
Prospective Studies
Registries
Stents*
Survival Rate
Grant Support
ID/Acronym/Agency:
HL-33292/HL/NHLBI NIH HHS; U01 HL033292-15/HL/NHLBI NIH HHS; U01 HL033292-16/HL/NHLBI NIH HHS; U01 HL033292-17/HL/NHLBI NIH HHS; U01 HL033292-18/HL/NHLBI NIH HHS; U01 HL033292-19/HL/NHLBI NIH HHS; U01 HL033292-20/HL/NHLBI NIH HHS; U01 HL033292-21/HL/NHLBI NIH HHS; U01 HL033292-22/HL/NHLBI NIH HHS; U01 HL033292-23/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
0/Hydroxymethylglutaryl-CoA Reductase Inhibitors
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Impact of different diagnostic criteria on the prevalence and prognostic significance of exertional ...
Next Document:  Guideline-oriented ambulatory lipid-lowering therapy of patients at high risk for cardiovascular eve...